Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock closed at 38.86 per share at the end of the most recent trading day (a 1.62% change compared to the prior day closing price) with a volume of 375.83K shares and market capitalization of 1.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Arcturus Therapeutics Holdings Inc. CEO is Joseph E. Payne.

The one-year performance of Arcturus Therapeutics Holdings Inc. stock is 101.03%, while year-to-date (YTD) performance is -10.42%. ARCT stock has a five-year performance of 18.12%. Its 52-week range is between 19.45 and 129.71, which gives ARCT stock a 52-week price range ratio of 17.60%

Arcturus Therapeutics Holdings Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 2.67, a price-to-sale (PS) ratio of 153.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.83%, a ROC of -30.89% and a ROE of -34.17%. The company’s profit margin is -84.18%, its EBITDA margin is -490.70%, and its revenue ttm is $6.89 Million , which makes it $0.26 revenue per share.

Of the last four earnings reports from Arcturus Therapeutics Holdings Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.16 for the next earnings report. Arcturus Therapeutics Holdings Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Arcturus Therapeutics Holdings Inc. is Strong Buy (1.25), with a target price of $86, which is +121.31% compared to the current price. The earnings rating for Arcturus Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcturus Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcturus Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 30.85, ATR14 : 4.89, CCI20 : -32.34, Chaikin Money Flow : -0.07, MACD : -7.30, Money Flow Index : 35.47, ROC : -2.07, RSI : 39.61, STOCH (14,3) : 45.69, STOCH RSI : 1.00, UO : 43.92, Williams %R : -54.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcturus Therapeutics Holdings Inc. in the last 12-months were: Andrew H. Sassine (Buy at a value of $148 700), Joseph E. Payne (Buy at a value of $63 380), Keith C. Kummerfeld (Buy at a value of $29 997), Padmanabh Chivukula (Sold 70 000 shares of value $4 155 200 )